BioCopy and YUMAB announce partnership to fight cancer
The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy
The greatest challenge in oncology today is to destroy cancer cells as precisely and accurately as possible without affecting healthy tissue. The focus is on short protein sequences (peptides) presented on the surface of tumor cells by an HLA protein. These pHLA complexes represent attractive targets for innovative immunotherapies. They are the new hope for curing cancer.
pHLA complexes are biologically highly complex. The challenge is to target them as accurately and precisely as possible with a suitable antibody.
The goal of the collaboration is to establish a new powerful platform (safeTY-engager®) to accelerate the development of T cell engagers. T-cell engagers are bi-specific antibodies that bring T cells close to tumor cells for targeted killing. They have to bind specifically and without side effects to the chosen pHLA tumor target as well as to the T cell. Only when they connect to both, the tumor can be destroyed. The project is funded by the German Federal Ministry of Education and Research (BMBF) with a total of EUR 1.1 million.
BioCopy and YUMAB combine their core competencies. BioCopy's screening technology plays the key role in characterizing potential drug candidates regarding their specific binding to pHLA tumor targets. With the BioCopy technology the complex selection and optimization process of promising drug candidates can be accelerated and monitored.
YUMAB has extensive expertise in the development of therapeutic antibodies. With its unique recombinant technology platform, antibody drugs can be developed from target to optimized lead candidate for the clinic within a short time.
Through this collaboration, BioCopy and YUMAB combine their technologies and expertise to achieve new levels of efficiency for the development of immuno-oncology therapeutics in the emerging field of pHLA tumor targets.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
